ArisGlobal, a provider of solutions to the life science industry, has announced the immediate availability of agEncoder 2.1, its comprehensive coding and dictionary management system.
The new release, certified by the Uppsala Monitoring Center to utilize the full features of WHO DRUG dictionary, offers new capabilities such as multi-lingual MedDRA support (including English, French, German, Italian, Japanese, Spanish, Portuguese, Czech, Hungarian and Dutch). agEncoder also extends support of standardized MedDRA Queries (SMQs) and Custom MedDRA Queries (CMQs) including improved search capabilities and full impact analysis of new MedDRA versions.
Integrated with ArisGlobal’s pharmacovigilance and safety system (ARISg) and the company’s electronic data capture technology (agCapture), agEncoder offers comprehensive dictionary management and centralized coding with integrated workflow to ensure accurate and consistent coding of clinical terms. Further functionality enhancements include improved search capability of the WHO-DD browser (e.g. search for active ingredients, search for preferred terms, generic terms, drug synonyms and umbrella search) and the use of eSignature.
Commented Mathias Poensgen, product manager. “agEncoder 2.1 serves the coding needs of both pharmacovigilance and clinical teams to improve the quality as well as the efficiency of their coding process.”
agEncoder 2.1 will be available to customers as a licensed, on-premise solution or as a hosted solution via agOnDemand™, ArisGlobal's comprehensive Software-as-a-Service (SaaS) delivery platform.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.